NALIRIFOX Demonstrates Consistent Safety in Metastatic Pancreatic Cancer


Patients with metastatic pancreatic ductal adenocarcinoma who receive NALIRIFOX tend to have more gastrointestinal toxicity while nab-paclitaxel/gemcitabine results in more cytopenias, according to an expert from University of California, Los Angeles.

The safety profile of first-line liposomal irinotecan (Onivyde) plus 5 fluorouracil/leucovorin and oxaliplatin (NALIRIFOX) in patients with metastatic pancreatic ductal adenocarcinoma was consistent with those previously reported findings, according to Zev A. Wainberg, MD, regarding the phase 3 NAPOLI-3 study (NCT04083235).

In an interview with CancerNetwork®, lead author Wainberg, a professor of medicine at the University of California, Los Angeles (UCLA) and co-director of the UCLA Gastrointestinal Oncology Program, discussed the safety of NALIRIFOX compared with gemcitabine plus nab-paclitaxel from the NAPOLI-3 study, which was presented at the 2023 Gastrointestinal Cancers Symposium.

In NAPOLI-3, common grade 3/4 treatment-emergent adverse effects observed in patients receiving NALIRIFOX vs those receiving gemcitabine plus nab-paclitaxel, respectively, included diarrhea (20.3% vs 4.5%), nausea (11.9% vs 2.6%), hypokalemia (15.1% vs 4.0%), anemia (10.5% vs 17.4%), and neutropenia (14.1% vs 24.5%).

Wainberg also discussed the trial’s limitations, which included the fact that it was not placebo controlled.


Most of the safety data are consistent with what we knew of these regimens. The NALIRIFOX had more GI toxicity than gemcitabine/nab-paclitaxel, and the gemcitabine/nab-paclitaxel had more cytopenias than NALIRIFOX. However, we were pleasantly pleased by a low rate of peripheral neuropathy in our study which, in the NALIRIFOX arm, indicated a lower dose of the cumulative oxaliplatin usage and that had important implications. Those were some of the main safety findings in the NAPOLI-3 trial.

There are always limitations to a study. It wasn’t placebo-controlled. There are certainly biases about which patients [should br included.] But this study took a really bread and butter group of patients, which is newly diagnosed metastatic pancreatic cancer, in centers all around the world, not in academic centers and community centers. There was not a huge number of differences in this kind of study than what we would expect in the real world.


Wainberg ZA, Melisi D, Macarulla T, et al. NAPOLI-3: A randomized, open-label phase 3 study of liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). J Clin Oncol. 2023;41(suppl 4):LBA661. doi:10.1200/JCO.2023.41.3_suppl.LBA661

Related Videos
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
The use of proton therapy may offer a more specific depth charge compared with conventional radiation, according to Timothy Chen, MD.
ZAP-X may provide submillimeter accuracy when administering radiation to patients with brain tumors.
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
The toxicity profile of tislelizumab also appears to look better compared with chemotherapy in metastatic esophageal squamous cell carcinoma.
Patients with unresectable or metastatic esophageal squamous cell carcinoma and higher PD-L1 expression may benefit from treatment with tislelizumab, according to Syma Iqbal, MD.
Quantifying disease volume to help identify potential recurrence following surgery may be a helpful advance, according to Sean Dineen, MD.
Sean Dineen, MD, highlights the removal of abdominal wall lesions and other surgical strategies that may help manage symptoms in patients with cancer.